Malaria's next threat: drug-resistant parasites spread even after treatment

NCT ID NCT06347471

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosquito feeding tests to measure how many mosquitoes got infected before, during, and after treatment. The goal was to see if resistant parasites are more likely to be transmitted than non-resistant ones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Artemether-lumefantrine (Coartem) and dihydroartemisinin-piperaquine (Eurartesim)

What this could lead to

If successful, this could help public health officials understand how drug-resistant malaria spreads and guide strategies to contain it.

What could go wrong

This is a small, completed observational study (160 participants) in one region, so results may not apply broadly. It measures transmission in the lab, not real-world spread.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALCIPARUM; MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Dr. Ambrosoli Memorial Hospital

    Kalongo, Agago District, Uganda

  • Patongo Health Facility IV

    Patongo, Agago District, Uganda